





|                              |  | EMLc               | Codes ATC: J01DD01 |
|------------------------------|--|--------------------|--------------------|
| Indication                   | Other specified pneumonia  | Code ICD11: CA40.Y |                    |
| INN                          | Cefotaxime   |                    |                    |
| Type de médicament           | Chemical agent   |                    |                    |
| Groupes d'antibiotiques      |  WATCH  |                    |                    |
| Type de liste                | Liste de base (EML) (EMLc)   |                    |                    |
| Additional notes             | 3rd generation cephalosporin of choice for use in hospitalized neonates.   |                    |                    |
| Formulations                 | Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt) ; 500 mg in vial powder for injection (as sodium salt) ; 1 g in vial powder for injection (as sodium salt) ; 2 g in vial powder for injection (as sodium salt) |                    |                    |
| Historique des statuts LME   | Ajouté pour la première fois en 2017 (TRS 1006)<br>Modifié en 2023 (TRS 1049)  |                    |                    |
| Sexe                         | Tous   |                    |                    |
| Âge                          | Aussi recommandé pour les enfants  |                    |                    |
| Équivalence thérapeutique    | La recommandation concerne ce médicament spécifique  |                    |                    |
| Renseignements sur le brevet | Patents have expired in most jurisdictions<br>Lire la suite <a href="#">sur les brevets.</a>    |                    |                    |
| Wikipédia                    | <a href="#">Cefotaxime</a>    |                    |                    |
| DrugBank                     | <a href="#">Cefotaxime</a>    |                    |                    |

### Recommandation du comité d'experts

The Expert Committee recommended the inclusion of a new strength, child-friendly dispersible tablet formulation of amoxicillin + clavulanic acid (200 mg + 28.5 mg) as an Access group antibiotic on the core list of the EMLc for treatment of bacterial infections in children – specifically those infections for which amoxicillin + clavulanic acid is already recommended on the EMLc. The Committee noted that the 7:1 ratio of amoxicillin to clavulanic acid is associated with similar efficacy to the 4:1 ratio but has a reduced frequency of gastrointestinal adverse effects. The Committee endorsed the importance of age-appropriate formulations to better meet the dosing needs of children. Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of a new formulation of amoxicillin + clavulanic acid (dispersible tablet 250 mg + 62.5 mg) to the EMLc. - the addition of new strength formulations of cefotaxime (powder for injection: 500 mg; 1 g; 2 g (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc.

### Recommandations de la LME : Other specified pneumonia

Premier choix

Second choix

**HOSPITAL-ACQUIRED PNEUMONIA**

piperacillin + tazobactam

amoxicillin + clavulanic acid

cefotaxime

ceftriaxone

